logo-loader
viewZelira Therapeutics Ltd

Zelda Therapeutics doses first patient in insomnia clinical trial

The study is being led by one of Australia’s leading sleep research centres.

women in bed with pillow over her ears
Preliminary results from the clinical trial are expected in the first half of next year

Zelda Therapeutics Ltd (ASX:ZLD) has dosed the first patient in its pioneering medical cannabis insomnia clinical trial.

A randomised, placebo-controlled, crossover study design will be used to treat 24 patients with Zelda’s medicinal cannabis formulation.

The study will collect and analyse data to determine the effect of the Zelda formulation on the time it takes to fall asleep, time spent awake and asleep during the night and quality of sleep.

Results from the trial are expected in the first half of 2019.

READ: Zelda Therapeutics enters German medical cannabis market with partnership

Dr Richard Hopkins, Managing Director of Zelda said, “This is a major milestone for Zelda as it represents the first of a number of clinicaltrials we’re planning to commence over the coming months.

“Positive data will enable Zelda to accelerate its commercialisation plans, which have been facilitated by our recent agreement with HAPA Medical to manufacture and distribute Zelda products in Germany and Europe.”


Bloomberg recently reported that US investors are piling into an exchange-traded fund (ETF) known as ETFMG Alternative Harvest ETF which tracks the Canadian cannabis industry.

This comes as the country moves toward legalisation and liquor producers show growing interest in selling cannabis.

The US-listed US$662 million cannabis ETF is up 20% over the past month.

Alcohol giants teaming up with cannabis companies

Recently, alcohol giant Constellation Brands Inc (NYSE:STZ) invested $3.8 billion in Canadian marijuana maker Canopy Growth Corp (NYSE:CGC).

This is the biggest deal to date in what is now a fast emerging industry and has played a key role in turning investors’ attention to the industry.

Quick facts: Zelira Therapeutics Ltd

Price: 0.053 AUD

ASX:ZLD
Market: ASX
Market Cap: $51.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read